Comparative effectiveness of several adjuvant therapies after hepatectomy for hepatocellular carcinoma patients with microvascular invasion

Table 2 The baseline characteristics of included studies

Ref.	Design	Enrollment period	Treatment	Sample size (n)	Male (n)	Age (yr)	Tumor size (cm)	Multiple nodules (n)	HBV (n)	Child-Pugh, A/B (n)
Li et al[8], 2021	Retrospective cohort, PSM	August 2009 to August 2017	Sorafenib	42	34/8	54.2 ± 1.4	6.2 ± 0.6	29	NA	42
			HT alone	42	35/7	54.6 ± 1.7	7.2 ± 0.8	25	NA	42
Zhang et al[17], 2019	Retrospective cohort, PSM	2009 to 2016	Sorafenib	113	97/16	49.0 (43.0-56.0)	5.9 (4.0-9.0)	17	102	111/2
			HT alone	113	98/15	48.0 (40.0-57.0)	5.42 (3.8-9.1)	21	98	112/1
Huang et al[18], 2019	Retrospective cohort	January 2009 to December 2016	Sorafenib	16	12	52.25 ± 11.94	NA	2	12	16/0
			HT alone	33	30	51.52 ± 11.87	NA	3	26	31/2
Li et al[9], 2023	RCT	June 2016 to August 2021	HAIC	143	122	51 (25-75)	5.5 (1.8-30.0)	43	125	142/1
			HT alone	143	126	54 (27-75	5.4 (1.5-16.0)	27	51	141/2
Hsiao et al[19], 2017	Retrospective cohort	2006 to 2014	HAIC	29	NA	NA	NA	NA	NA	NA
			HT alone	41	NA	NA	NA	NA	NA	NA
Shi et al[20], 2022	RCT	August 2015 to December 2016	RT	38	33	56.42 ± 10.44	4.87 ± 2.03	NA	36	NA
			HT alone	38	32	55.74 ± 10.19	4.88 ± 2.46	NA	36	NA
Wang et al[10], 2020	Retrospective cohort	July 2015 to December 2018	RT	29	24	55.90 ± 8.05	4.75 ± 2.15	2	29	29/0
			HT alone	30	25	56.57 ± 9.43	4.50 ± 2.98	2	30	30/0
Wang et al[21], 2019	Retrospective cohort, PSM	July 2008 to December 2016	RT	46	43	50.98 ± 10.53	5.39 ± 2.74	4	38	46/0
			TACE	46	37	51.52 ± 11.40	5.50 ± 3.07	5	36	46/0
Qiu et al[22], 2022	Retrospective cohort, PSM	April 2014 to July 2019	TACE	164	138	51 ± 12	4.7 ± 2.9	43	135	162/2
			HT alone	164	145	52 ± 12	5.0 ± 2.9	52	136	162/2
Wang et al[23], 2019	Retrospective cohort, PSM	September 2004 to December 2015	TAEC	57	47	55 ± 11	6 (2-14)	11	47/2	54/3
			HT alone	57	51	56 ± 10	6 (2-18)	11	47/6	54/3
Qi et al[24], 2019	Prospective cohort	January 2012 to December 2014	TACE	91	78	NA	NA	23	77	54/37
			HT alone	109	93	NA	NA	25	96	76/33
Wei et al[7], 2018	RCT	June 2009 to December 2012	TACE	116	106	44.0 (18-75)	5	0	94/NA	116/0
			HT alone	118	106	48.5 (18-74)	5	0	101/NA	116/2
Wang et al[25], 2018	Retrospective cohort	January 2010 to December 2014	TACE	44	42	52.07 ± 7.24	3.84 ± 1.27	44	NA	41/1
			HT alone	84	76	54.49 ± 10.18	3.83 ± 1.09	84	NA	82/2
Sun et al[26], 2016	Retrospective cohort	January 2004 to June 2013	TACE	137	120	48.88 ± 0.87	6.51 ± 0.27	11	121	135/2
			HT alone	185	167	49.91 ± 0.72	6.99 ± 0.29	17	163	182/3

PSM: Propensity score matching; RCT: Randomized controlled trial; HT: Hepatectomy; HAIC: Hepatic artery infusion chemotherapy; RT: Radiotherapy; TACE: Transarterial chemoembolization; NA: Not available; HBV: Hepatitis B virus.